Skip to main content
. 2021 Sep 9;95(19):e00461-21. doi: 10.1128/JVI.00461-21

FIG 5.

FIG 5

Intraperitoneal delivery of CasRx. (A) Schematic representation of intraperitoneal injection of the CasRx system in vivo. (B) The mRNA levels of CP decreased after intraperitoneal injection of CasRx-dNLS targeting CP2 and RdRp2, but injection of mix-crRNA (CP2-crRNA and RdRp2-crRNA together) did not decrease the mRNA level. (C) The mRNA levels of RdRp decreased after intraperitoneal injection of CasRx-dNLS targeting CP2 and RdRp2, but injection of mix-crRNA (CP2-crRNA and RdRp2-crRNA together) did not decrease the mRNA level. (C) The mRNA levels of CP decreased after intraperitoneal injection of CasRx-NLS targeting CP2 and RdRp2, but injection of mix-crRNA (CP2-crRNA and RdRp2-crRNA together) did not decrease the mRNA level. (D) The mRNA levels of RdRp decreased after intraperitoneal injection of CasRx-NLS targeting CP2 and RdRp2, but injection of mix-crRNA (CP2-crRNA and RdRp2-crRNA together) did not decrease the mRNA level. (E) Values indicate the cumulative mortality rates for each group of groupers during the 14-day experimental period after intraperitoneal injection of CasRx-dNLS and CP2-crRNA, RdRp2-crRNA, or mix-crRNA. (F) Values indicate the cumulative mortality rates for each group of groupers during the 14-day experimental period after intraperitoneal injection of CasRx-NLS and CP2-crRNA, RdRp2-crRNA, or mix-crRNA. *, P < 0.05; **, P < 0.01; ns, not significant.